{"id":181,"date":"2019-12-02T13:23:55","date_gmt":"2019-12-02T17:23:55","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=181"},"modified":"2019-12-02T13:23:55","modified_gmt":"2019-12-02T17:23:55","slug":"with-a-flurry-of-warning-letters-and-a-consumer-update-fda-signals-commitment-to-cbd-enforcement-policy","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/12\/02\/with-a-flurry-of-warning-letters-and-a-consumer-update-fda-signals-commitment-to-cbd-enforcement-policy\/","title":{"rendered":"With a Flurry of Warning Letters and a Consumer Update, FDA Signals Commitment to CBD Enforcement Policy"},"content":{"rendered":"<p>On November 25, 2019, the U.S. Food &amp; Drug Administration (FDA) announced that it had\u00a0<a title=\"FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns\" href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-warns-15-companies-illegally-selling-various-products-containing-cannabidiol-agency-details\" target=\"_blank\" rel=\"noopener noreferrer\">issued warning letters<\/a>\u00a0to 15 U.S. businesses engaged in the sale of products containing cannabidiol (CBD); that it had published a revised\u00a0<a title=\"What You Need to Know (And What We\u2019re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD\" href=\"https:\/\/www.fda.gov\/consumers\/consumer-updates\/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis\" target=\"_blank\" rel=\"noopener noreferrer\">Consumer Update<\/a>\u00a0detailing safety concerns about CBD products; and that it \u201ccannot conclude that CBD is generally recognized as safe (GRAS)\u201d for use in human or animal food. These actions and statements by FDA cut against industrywide hopes that FDA might soon realign its enforcement policy in light of market realities.<\/p>\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/flurry_warning_letters_consumer_update_fda_signals_commitment_cbd_enforcement_policy_1219.html\">View the full <em>Alert<\/em> on the Duane Morris LLP website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On November 25, 2019, the U.S. Food &amp; Drug Administration (FDA) announced that it had\u00a0issued warning letters\u00a0to 15 U.S. businesses engaged in the sale of products containing cannabidiol (CBD); that it had published a revised\u00a0Consumer Update\u00a0detailing safety concerns about CBD products; and that it \u201ccannot conclude that CBD is generally recognized as safe (GRAS)\u201d for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/12\/02\/with-a-flurry-of-warning-letters-and-a-consumer-update-fda-signals-commitment-to-cbd-enforcement-policy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;With a Flurry of Warning Letters and a Consumer Update, FDA Signals Commitment to CBD Enforcement Policy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[374,360,29,376,209,419,388,172],"ppma_author":[521],"class_list":["post-181","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-cannabis","tag-cbd","tag-fda","tag-fda-cannabis","tag-frederick-ball","tag-hemp","tag-justin-stern","tag-warning-letter"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=181"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/181\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=181"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}